#USA #Boston #Haemonetics #Frank Chan #Roy Galvin

Haemonetics Strengthens Leadership Team

Haemonetics Corporation, a prominent player in the global medical technology arena, has made notable changes to its executive leadership team aimed at enhancing its operational capabilities and expanding market reach. On March 3, 2025, the company announced the appointment of Frank Chan as the new Executive Vice President and Chief Operating Officer, as well as the elevation of Roy Galvin to Executive Vice President and Chief Commercial Officer.

New Executive Roles

Frank Chan, a seasoned executive with an impressive background, will officially assume his role on April 7, 2025. He comes to Haemonetics with more than 25 years of experience in the medical device sector and healthcare technology. Formerly with Medtronic, where he led Acute Care Monitoring, Chan has a track record of driving innovation and operational excellence in organizations of significant scale. As COO, he will be responsible for directing research and development, regulatory affairs, and overseeing the company's global manufacturing and supply chain operations.

Roy Galvin, who joined Haemonetics in 2022 as President of Global Plasma and Blood Center, is now set to lead the company's Global Hospital business and all commercialization initiatives. His extensive background in global healthcare technology spans over 25 years, with prior experience at Medtronic in the Neuroscience and Orthopedic divisions. This expanded role underlines Haemonetics’ commitment to enhancing its product portfolio and service offerings.

Strategic Vision

Chris Simon, the President and CEO of Haemonetics, emphasized that these leadership changes are critical to executing the company’s long-range growth strategy. He stated, "With the addition of Frank Chan and Roy Galvin's expanded role, we aim to bolster our competitive advantage and lay the groundwork for sustained success."

These strategic appointments come at a pivotal time as Haemonetics seeks to innovate and lead in the healthcare technology space, particularly in blood and plasma collection, surgical suite operations, and hospital transfusion services. The company is focused on enhancing patient care while also striving to reduce healthcare costs through advanced technologies and comprehensive solutions.

The Road Ahead

With these new executive appointments, Haemonetics is gearing up for the next phase of its ambitious growth plan. By harnessing Frank Chan’s operational expertise and Roy Galvin’s commercial acumen, the company is poised to effectively navigate the complexities of the healthcare industry.

Haemonetics Corporation has a robust portfolio of medical solutions that directly impact patient care. Their dedication to innovation is evident in their ongoing efforts to advance technology in the field of blood management. For more information on their innovative solutions and updates, interested parties can visit their official website at www.haemonetics.com.

As the healthcare landscape continues to evolve, Haemonetics is committed to improving outcomes for patients and healthcare providers alike. The executive changes serve not only as a catalyst for growth but also reflect the company’s dedication to remaining at the forefront of medical technology advancements.